Mohammad H Shakhatreh1, Zhigang Duan2, Nathaniel Avila2, Aanand D Naik2, Jennifer R Kramer2, Marilyn Hinojosa-Lindsey2, John Chen2, Hashem B El-Serag3. 1. Section of Health Services Research, Houston Veterans Affairs Health Services Research and Development Center of Excellence, Houston, Texas; Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, Texas. 2. Section of Health Services Research, Houston Veterans Affairs Health Services Research and Development Center of Excellence, Houston, Texas. 3. Section of Health Services Research, Houston Veterans Affairs Health Services Research and Development Center of Excellence, Houston, Texas; Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, Texas. Electronic address: hasheme@bcm.edu.
Abstract
BACKGROUND & AIMS: Practice guidelines recommend a 1-time screening endoscopy for patients with gastroesophageal reflux disease (GERD) who are at high risk for Barrett's esophagus or malignancy. However, little is known about the risk of cancer in patients with negative findings from screening endoscopies. METHODS: We conducted a retrospective cohort study using data from 121 Veterans Health Administration facilities nationwide to determine the incidence rate of esophageal adenocarcinoma (EA) separately, as well as any upper gastrointestinal cancers, in patients with an initial negative screening endoscopy (esophagogastroduodenoscopy [EGD]). We included veteran patients with GERD diagnosed between 2004 and 2009 who had a negative screening EGD within 1 year of diagnosis. We estimated the incidence rate of EA, and any upper gastrointestinal cancer, in patients with GERD who had a negative screening EGD. We examined differences in demographic, clinical, and facility factors among patients with and without cancer. RESULTS: We identified 68,610 patients with GERD and a negative screening EGD (mean age, 55.5 y; 90% men; 67.5% white). During a mean follow-up period of 3.2 years, 10 patients developed EA and 29 patients developed any upper gastrointestinal malignancies, including EA. The incidence of subsequent EA in this group was 4.6/100,000 patient-years of follow-up evaluation, whereas the incidence of any upper gastrointestinal cancers was 13.2/100,000 patient-years of follow-up evaluation. Patients with a subsequent cancer were significantly older and had higher comorbidity scores than patients without cancer. Other clinical and facility factors did not differ significantly between these 2 groups. CONCLUSIONS: The risk of cancer is low, over a mean 3-year period, for patients with GERD who had a negative screening endoscopy. These findings justify recommendations for a 1-time screening endoscopy for patients with GERD.
BACKGROUND & AIMS: Practice guidelines recommend a 1-time screening endoscopy for patients with gastroesophageal reflux disease (GERD) who are at high risk for Barrett's esophagus or malignancy. However, little is known about the risk of cancer in patients with negative findings from screening endoscopies. METHODS: We conducted a retrospective cohort study using data from 121 Veterans Health Administration facilities nationwide to determine the incidence rate of esophageal adenocarcinoma (EA) separately, as well as any upper gastrointestinal cancers, in patients with an initial negative screening endoscopy (esophagogastroduodenoscopy [EGD]). We included veteran patients with GERD diagnosed between 2004 and 2009 who had a negative screening EGD within 1 year of diagnosis. We estimated the incidence rate of EA, and any upper gastrointestinal cancer, in patients with GERD who had a negative screening EGD. We examined differences in demographic, clinical, and facility factors among patients with and without cancer. RESULTS: We identified 68,610 patients with GERD and a negative screening EGD (mean age, 55.5 y; 90% men; 67.5% white). During a mean follow-up period of 3.2 years, 10 patients developed EA and 29 patients developed any upper gastrointestinal malignancies, including EA. The incidence of subsequent EA in this group was 4.6/100,000 patient-years of follow-up evaluation, whereas the incidence of any upper gastrointestinal cancers was 13.2/100,000 patient-years of follow-up evaluation. Patients with a subsequent cancer were significantly older and had higher comorbidity scores than patients without cancer. Other clinical and facility factors did not differ significantly between these 2 groups. CONCLUSIONS: The risk of cancer is low, over a mean 3-year period, for patients with GERD who had a negative screening endoscopy. These findings justify recommendations for a 1-time screening endoscopy for patients with GERD.
Authors: Ji Hyung Nam; Il Ju Choi; Soo-Jeong Cho; Chan Gyoo Kim; Jae Kwan Jun; Kui Son Choi; Byung-Ho Nam; Jun Ho Lee; Keun Won Ryu; Young-Woo Kim Journal: Cancer Date: 2012-07-16 Impact factor: 6.860
Authors: Katie S Nason; Promporn Paula Wichienkuer; Omar Awais; Matthew J Schuchert; James D Luketich; Robert W O'Rourke; John G Hunter; Cynthia D Morris; Blair A Jobe Journal: Arch Surg Date: 2011-07
Authors: Joel H Rubenstein; James M Scheiman; Shahram Sadeghi; David Whiteman; John M Inadomi Journal: Am J Gastroenterol Date: 2010-12-07 Impact factor: 10.864
Authors: D C Farrow; T L Vaughan; C Sweeney; M D Gammon; W H Chow; H A Risch; J L Stanford; P D Hansten; S T Mayne; J B Schoenberg; H Rotterdam; H Ahsan; A B West; R Dubrow; J F Fraumeni; W J Blot Journal: Cancer Causes Control Date: 2000-03 Impact factor: 2.506
Authors: Michal F Kaminski; Jaroslaw Regula; Ewa Kraszewska; Marcin Polkowski; Urszula Wojciechowska; Joanna Didkowska; Maria Zwierko; Maciej Rupinski; Marek P Nowacki; Eugeniusz Butruk Journal: N Engl J Med Date: 2010-05-13 Impact factor: 91.245
Authors: Anne F Peery; Evan S Dellon; Jennifer Lund; Seth D Crockett; Christopher E McGowan; William J Bulsiewicz; Lisa M Gangarosa; Michelle T Thiny; Karyn Stizenberg; Douglas R Morgan; Yehuda Ringel; Hannah P Kim; Marco Dacosta DiBonaventura; Charlotte F Carroll; Jeffery K Allen; Suzanne F Cook; Robert S Sandler; Michael D Kappelman; Nicholas J Shaheen Journal: Gastroenterology Date: 2012-08-08 Impact factor: 22.682
Authors: Judith J de Jong; Marten A Lantinga; Ina M E Thijs; Philip R de Reuver; Joost P H Drenth Journal: Therap Adv Gastroenterol Date: 2020-11-04 Impact factor: 4.409
Authors: Mona Zamanian-Azodi; Mostafa Rezaei-Tavirani; Hadi Hasanzadeh; Sara Rahmati Rad; Sona Dalilan Journal: Gastroenterol Hepatol Bed Bench Date: 2015